Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03737994
Title Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Lorlatinib

Carboplatin + Lorlatinib

Ceritinib

Alectinib + Cisplatin

Alectinib + Carboplatin

Ceritinib + Cisplatin

Pemetrexed Disodium

Carboplatin + Ceritinib

Cisplatin + Ensartinib

Carboplatin + Ensartinib

Brigatinib + Cisplatin

Brigatinib

Alectinib

Brigatinib + Carboplatin

Ensartinib

Cisplatin + Pemetrexed Disodium

Crizotinib

Carboplatin + Pemetrexed Disodium

Lorlatinib

Age Groups: adult | senior
Covered Countries USA